Ironwood Pharmaceuticals, Inc.
NASDAQIronwood Pharmaceuticals heads into the back half of August with a notable divergence at its core — short sellers are unwinding positions even as the stock trades at a fraction of where analysts think it should be. The short interest story has shifted materially over the past week. At 10% of free float, the position remains elevated by any measure, but the direction is clearly…
Snapshot as of 26 Aug 2026
Ironwood Pharmaceuticals heads into the back half of August with a notable divergence at its core — short sellers are unwinding positions even as the stock trades at a fraction of where analysts think it should be. The…
Ironwood Pharmaceuticals heads into its August 6 print with a rare and pointed tension: the stock is up 14% on the week, yet bears are pressing harder, not folding. Short interest has climbed nearly 20% over the past…
Ironwood Pharmaceuticals enters its August 6 earnings print in an unusual spot: the stock has rallied 14% on the week to $4.23, yet short interest has been climbing steadily all month, setting up a tug-of-war between…
Ironwood Pharmaceuticals woke up Wednesday with its most significant piece of positive news in months — an FDA approval expanding LINZESS (linaclotide) to pediatric patients aged two and older for functional…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IRWD — free to start on ORTEX.
Sign up for free →Open IRWD on ORTEX